Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. (IKT) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · IKT · as of Jun 10, 2026
Key Statistics
Explore Inhibikase Therapeutics, Inc. Data
ikt stock data · financialsAbout Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. operates as a pharmaceutical firm in the clinical development stage, concentrating its efforts on pioneering treatments for Parkinson's Disease (PD) and a range of associ…
what is inhibikase therapeutics, inc. · ikt stock overview · inhibikase therapeutics, inc. company profile · who is inhibikase therapeutics, inc. ceo · ikt NASDAQ · inhibikase therapeutics, inc. headquarters · inhibikase therapeutics, inc. business segments
About Stock Overview & Key Data
Inhibikase Therapeutics, Inc. (IKT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Dec 23, 2020. As of the latest trading session, IKT stock price is $1.62, with a market capitalization of $213.9M. The stock has returned — over the past 12 months and — year-to-date.
Frequently Asked Questions
As of the latest trading session, Inhibikase Therapeutics, Inc. (IKT) stock price is $1.62. The stock is traded on NASDAQ under the ticker symbol IKT. The 52-week range is $1.33 – $2.26.